Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 18/20 | 0.43 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.38 |
| ▸ | WIZ | O95785 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25690868 | 0.90 | IKZF1 (0.44) | CRBNIKZF1WIZ | |
| SCHEMBL25690785 | 0.90 | IKZF1 (0.44) | CRBNIKZF1WIZ | |
| SCHEMBL24411173 | 0.81 | CRBN (0.47) | CRBN | |
| SCHEMBL24827955 | 0.80 | CRBN (0.69) | CRBNIKZF1 | |
| SCHEMBL20128623 | 0.80 | CRBN (0.69) | CRBNIKZF1 | |
| SCHEMBL25690793 | 0.79 | CRBN (0.39) | CRBNIKZF1 | |
| SCHEMBL25690782 | 0.79 | CRBN (0.39) | CRBNIKZF1 | |
| SCHEMBL25690787 | 0.79 | CRBN (0.39) | CRBNIKZF1 | |
| SCHEMBL25690766 | 0.79 | CRBN (0.40) | CRBN | |
| SCHEMBL25690773 | 0.79 | CRBN (0.40) | CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230150973-A1 | NOVEL UREAS HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230135173-A1 | NOVEL SUBSTITUTED QUINOLINE-8-CARBONITRILE DERIVATIVES HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230135173-A1 | NOVEL SUBSTITUTED QUINOLINE-8-CARBONITRILE DERIVATIVES HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | AR, NR5A1, ESRRA | CRBN 409/4885IKZF1 3668/4885WIZ 4853/4885 |
| US-20230150973-A1 | NOVEL UREAS HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | AR, UTS2R, ESRRA | CRBN 1041/4885IKZF1 3057/4885WIZ 4622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.